Robert Noonan, MD
Family Medicine · Clarksville, ARNPI 1902867070
Payments from drug & device makers
Across 253 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$885
- Sunovion Pharmaceuticals Inc.$403
- Novo Nordisk$399
- AstraZeneca$236
- Pfizer$235
- GSK$217
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,804100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $885 |
| Sunovion Pharmaceuticals Inc. | 27 | $403 |
| Novo Nordisk | 24 | $399 |
| AstraZeneca(2 entities) | 15 | $236 |
| Pfizer | 14 | $235 |
| GSK | 10 | $217 |
| Lilly USA, LLC | 14 | $197 |
| Boehringer Ingelheim | 11 | $196 |
| Sanofi-aventis U.S. LLC | 14 | $126 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $100 |
| Boston Scientific | 4 | $78 |
| Abbott | 4 | $69 |
| Merck | 3 | $65 |
| Amarin Pharma, Inc. | 3 | $59 |
| Johnson & Johnson | 4 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Procept Biorobotics Corporation | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Novartis | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Amgen | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $11 |
How this compares
$3,805 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $89,678 |
| OzempicSemaglutide | 57 | $63,460 |
| FarxigaDapagliflozin Propanediol | 49 | $45,219 |
| MounjaroTirzepatide | 21 | $42,853 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $38,940 |
| XareltoRivaroxaban | 39 | $35,290 |
| JanuviaSitagliptin Phosphate | 37 | $34,444 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $15,680 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $13,295 |
| JardianceEmpagliflozin | 18 | $12,656 |
| EntrestoSacubitril/Valsartan | 17 | $11,061 |
| LinzessLinaclotide | 15 | $10,324 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $9,231 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,404 |
| Novolog FlexpenInsulin Aspart | 15 | $7,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $235 | $89,678113 claims |
| Novo NordiskOzempic | $399 | $63,46057 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $217 | $59,34692 claims |
| AstraZenecaFarxiga | $236 | $45,21949 claims |
| Lilly USA, LLCMounjaro | $197 | $42,85321 claims |
| Johnson & JohnsonXarelto, Invokamet | $54 | $41,48350 claims |
| MerckJanuvia | $65 | $34,44437 claims |
| Boehringer IngelheimJardiance | $196 | $12,65618 claims |
| NovartisEntresto | $18 | $11,06117 claims |
| AbbVieLinzess | $885 | $10,32415 claims |
| Sanofi-aventis U.S. LLCLantus | $126 | $2,08920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Clarksville
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.